





Cognitive Trajectories in DIAN: Relationships with Symptom Onset, Mutation Types, and Clinical Status

Jason Hassenstab, PhD

Assistant Professor of Neurology and Psychological & Brain Sciences Washington University in St. Louis

Disclosures



No relevant disclosures

Research Support

- NIH K23DK094982
- Charles F. and Joanne Knight Alzheimer's Initiative

Consultant

- GLG Council
- Biogen

Clinical Trials

 Cognition Core Director, DIAN-TU

DIAN Aims: Cognition



- How is cognition different between Non-Carriers and Mutation Carriers?
 - Similar pattern to late-onset AD?
- Differences between CDR 0 Mutation Carriers and Non-Carriers?
- What is the influence of estimated years to symptom onset (EYO)?
- Differences between mutation types (PS1,PS2,APP)

Current DIAN Cognitive Battery



Episodic Memory	Attentional Control	Working Memory
DIAN Word List Test	Semantic Categorization	Computation Span
WMS-R Logical Memory	Simon Flanker Task	Reading Span
Pair Binding	Consonant-Vowel,	WMS-R Digit Span
	Odd-Even Switching Task	
Processing Speed	Semantic Memory	DIAN-TU Composite
WAIS-R Digit Symbol	Boston Naming Test	MMSE
Trailmaking Test Part A	Category Fluency	DIAN Word List Test
Trailmaking Test Part B	Word Fluency	WMS-R Logical Memory

WAIS-R Digit Symbol



	Non-Mutation Carriers CDR = 0 (n = 174)	Mutation Carriers CDR = 0 (n = 157)	Mutation Carriers CDR = 0.5 (n = 64)	Mutation Carriers CDR >= 1 (n = 37)
Age (years)	38.9 (11.2)	34.8 (9.3)	43.7 (9.9)	49.0 (9.3)
Est. Years till Onset	-9.3 (11.6)	-12.9 (9.0)	-1.9 (6.9)	5.1 (4.3)
Sex (% Female)	59%	58%	56%	49%
APOE4 carriers (%)	27%	27%	31%	35%
PS1 PS2 APP (%)	65% 10% 25%	70% 12% 18%	80% 3% 17%	86% 0% 14%
Education (years)	14.6 (2.9)	14.6 (2.9)	13.6 (3.2)	13.0 (2.8)
MMSE	29.1 (1.2)	29.0 (1.2)	26.2 (3.1)	15.7 (7.2)



	Non-Mutation carriers CDR = 0	Mutation Carriers CDR = 0	Mutation Carriers CDR = 0.5	Mutation Carriers CDR >= 1	Totals
Completed One	174	157	64	37	432
Completed Two	83	84	46	22	235
Completed Three	20	19	30	7	76
Completed Four+	10	7	15	3	35



Statistical Models

- Linear Mixed Effects Regression
 - Fixed Effects:
 - Estimated Years to Symptom Onset (EYO), Gender, Education
 - Group: Non-Carrier (CDR 0), Asymptomatic Mutation Carriers (CDR 0), Symptomatic Mutation Carriers (CDR >0)
 - Group*EYO interaction
 - Random Terms:
 - Family membership, EYO, participant
 - *p* values calculated with Satterthwaite approximations
 - Effect size: "Cohen's D"
 - Baseline sample size used to estimate pooled variance

Age vs EYO

Dominantly Inherited Alzheimer Network



Age vs EYO





Cognitive Change across EYO: Carriers vs Non-Carriers





Cognitive Change across EYO: Non-Carriers vs CDR 0 Mutation Carriers



- Non-Carriers - CDR 0 Carriers - CDR >0 Carriers



Cognitive Change across EYO: Carriers vs Non-Carriers





Cognitive Change across EYO: Carriers vs Non-Carriers





- Non-Carriers - CDR 0 Carriers - CDR >0 Carriers

Cognitive Change across EYO





	Ν	Slope	p	Cohen's D
Non-Carriers	83	(ref)	(ref)	(ref)
CDR 0 Carriers	84	-0.030	0.019	0.321
CDR >0 Carriers	68	-0.070	<0.001	0.665

	Ν	Slope	p	Cohen's D
Non-Carriers	83	(ref)	(ref)	(ref)
CDR 0 Carriers	84	-0.012	0.043	0.262
CDR >0 Carriers	68	-0.102	<0.001	1.097



	Ν	Slope	p	Cohen's D
Non-Carriers	170	(ref)	(ref)	(ref)
CDR 0 Carriers	160	-0.031	0.068	0.150
CDR >0 Carriers	90	-0.056	<0.001	0.502

	Ν	Slope	p	Cohen's D
Non-Carriers	83	(ref)	(ref)	(ref)
CDR 0 Carriers	84	-0.030	0.019	0.321
CDR >0 Carriers	68	-0.070	<0.001	0.665



	Ν	Slope	p	Cohen's D
Non-Carriers	170	(ref)	(ref)	(ref)
CDR 0 Carriers	160	-0.021	0.081	0.151
CDR >0 Carriers	90	-0.078	<0.001	0.872

	Ν	Slope	p	Cohen's D
Non-Carriers	83	(ref)	(ref)	(ref)
CDR 0 Carriers	84	-0.012	0.043	0.262
CDR >0 Carriers	68	-0.102	<0.001	1.097

Summary



- Widespread differences between Non-Carriers and Mutation Carriers across nearly all domains of cognition.
- Declines in episodic memory and DIAN-TU composite evident in asymptomatic mutation carriers
- Age and EYO highly correlated, but EYO is a better indicator of declines in cognition
- No differences in cognitive decline across mutation types
- Cross-sectional data appears mirror longitudinal data in DIAN



Acknowledgments

Andrew Aschenbrenner, PhD Yen Ying Lim, PhD Chengjie Xiong, PhD Eric McDade, DO Guoqiao "Peter" Wang, PhD Denise Maue Dreyfus, MA John C. Morris, MD Randall Bateman, MD

DIAN Participants and Families

Acknowledgements Principle Investigator: RJ Bateman



Coordinating Center Cores

Admin – V Buckles/KL Paumier Clinical – JC Morris/L Swisher Biomarkers – AM Fagan Biostatistics – C Xiong Genetics – AM Goate Imaging – T Benzinger Informatics – D Marcus Neuropathology – NJ Cairns

DIAN Expanded Registry

E McDade E Ziegemeier D Levitch M Downey-Jones We gratefully acknowledge the DIAN participants and family members, DIAN Steering Committee, Knight ADRC, Alzheimer's Association, ADAD Forum, NIH UF1AG032438, DIAN Pharma Consortium, Pharma Partners –Avid, CogState, Anonymous Foundations and Regulatory Representatives.

Performance Sites (PI)

- United States: Washington Univ (Bateman), MGH/BWH (Chhattwal), Butler Hosp/Brown Univ (Salloway), Columbia Univ (Mayeux), Indiana Univ (Ghetti/Farlow), USC (Chui/Ringman), U of Pittsburgh (Berman), Mayo Clinic, Jacksonville (Graff-Radford)
- Europe: Institute of Neurology, Univ College London (Rossor), Ludwig-Maximilians-Universität München (Levin), University of Tübingen (Jucker)
- Australia: Prince of Wales Medical Research Institutes, Sydney (Schofield), Mental Health Health Research Institute, Melbourne (Masters), Edith Cowan Univ, Perth (Martins)
- Argentina: Fleni (Allegri)
- Japan: Hirosaki, Osaka City, Niigata and Tokyo (Mori)
- Korea: Asan Medical Center (Lee)



Episodic Memory declines by Mutation Type

